The Government approved the Biovigilance Programme of India; the Indian Pharmacopoeia Commission (IPC), Ghaziabad, will lead monitoring of adverse events from medicines and biologicals used in organ and tissue transplantation.
The 7th edition of the National Formulary of India (NFI 2026) was released: 34 chapters, 20 appendices, 653 drugs including 42 fixed-dose combinations and 30 immunologicals.
India has risen from 123rd (2009-2014) to 8th globally in contributions to the WHO patient-safety database.
About 1,150 ADR reporting centres operate nationwide and will be extended to primary healthcare.
Monitor adverse drug reactions (ADRs)
Key: Started July 2010 with AIIMS New Delhi as National Coordination Centre; NCC moved to IPC in April 2011
Monitor adverse events from medical devices
Key: Approved 6 July 2015; IPC has been its NCC since 2018
Monitor adverse reactions to blood transfusion
Key: Launched 10 December 2012; coordinated by the National Institute of Biologicals, Noida
Monitor adverse events from medicines and biologicals used in organ and tissue transplants, for donors and recipients
Key: Approved 2026; IPC in the lead role
Sets drug standards (Indian Pharmacopoeia), publishes the NFI, runs PvPI and MvPI; autonomous body under MoHFW, set up 2005, fully functional from 1 January 2009
Has maintained VigiBase for WHO since 1978
WHO's global database of individual case safety reports, created in 1968 under the WHO Programme for International Drug Monitoring
1st edition, Ministry of Health
2nd and 3rd editions
Responsibility for the NFI passes to IPC
4th, 5th and 6th editions
7th edition, 653 drugs, also online as NFI Online
A pharmacopoeia sets legally binding quality standards for drugs: purity, strength and tests. A formulary guides prescribers on using a drug: dose, indications, side effects and interactions. IPC publishes both for India.
GS Paper 2 > Health; GS Paper 3 > Science & Technology
General Awareness > Health Schemes and Bodies
Detecting, assessing and preventing adverse effects of medicines after they reach the market
Safety monitoring of cells, tissues and organs used in transplantation
WHO global adverse-reaction database, run by the Uppsala Monitoring Centre, Sweden